Jie Jin

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6303692/publications.pdf

Version: 2024-02-01

260 papers	6,942 citations	126907 33 h-index	76900 74 g-index
281 all docs	281 docs citations	281 times ranked	9869 citing authors

#	Article	IF	Citations
1	FTO Plays an Oncogenic Role in Acute Myeloid Leukemia as a N 6 -Methyladenosine RNA Demethylase. Cancer Cell, 2017, 31, 127-141.	16.8	1,139
2	R-2HG Exhibits Anti-tumor Activity by Targeting FTO/m6A/MYC/CEBPA Signaling. Cell, 2018, 172, 90-105.e23.	28.9	794
3	Gene mutation patterns and their prognostic impact in a cohort of 1185 patients with acute myeloid leukemia. Blood, 2011, 118, 5593-5603.	1.4	297
4	A distinct glucose metabolism signature of acute myeloid leukemia with prognostic value. Blood, 2014, 124, 1645-1654.	1.4	232
5	Platelet integrin Î±IIbÎ²3: signal transduction, regulation, and its therapeutic targeting. Journal of Hematology and Oncology, 2019, 12, 26.	17.0	196
6	Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China. Journal of Hematology and Oncology, 2017, 10, 69.	17.0	155
7	Oral Tetra-Arsenic Tetra-Sulfide Formula Versus Intravenous Arsenic Trioxide As First-Line Treatment of Acute Promyelocytic Leukemia: A Multicenter Randomized Controlled Trial. Journal of Clinical Oncology, 2013, 31, 4215-4221.	1.6	149
8	miR-196b directly targets both HOXA9/MEIS1 oncogenes and FAS tumour suppressor in MLL-rearranged leukaemia. Nature Communications, 2012, 3, 688.	12.8	138
9	Treatment of Patients with Relapsed or Refractory Mantleâ€“Cell Lymphoma with Zanubrutinib, a Selective Inhibitor of Bruton's Tyrosine Kinase. Clinical Cancer Research, 2020, 26, 4216-4224.	7.0	126
10	Prognostic significance of 2-hydroxyglutarate levels in acute myeloid leukemia in China. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 17017-17022.	7.1	125
11	Homoharringtonine-based induction regimens for patients with de-novo acute myeloid leukaemia: a multicentre, open-label, randomised, controlled phase 3 trial. Lancet Oncology, The, 2013, 14, 599-608.	10.7	119
12	miR-22 has a potent anti-tumour role with therapeutic potential in acute myeloid leukaemia. Nature Communications, 2016, 7, 11452.	12.8	113
13	Phase 3 study of nilotinib vs imatinib in Chinese patients with newly diagnosed chronic myeloid leukemia in chronic phase: ENESTchina. Blood, 2015, 125, 2771-2778.	1.4	102
14	A Single-Arm, Multicenter, Phase II Study of Camrelizumab in Relapsed or Refractory Classical Hodgkin Lymphoma. Clinical Cancer Research, 2019, 25, 7363-7369.	7.0	102
15	The simpler, the better: oral arsenic for acute promyelocytic leukemia. Blood, 2019, 134, 597-605.	1.4	95
16	Risk of HBV reactivation in patients with B-cell lymphomas receiving obinutuzumab or rituximab immunochemotherapy. Blood, 2019, 133, 137-146.	1.4	88
17	Copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (CHRONOS-3): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncology, The, 2021, 22, 678-689.	10.7	83
18	Rapid Diagnosis and Prognosis of de novo Acute Myeloid Leukemia by Serum Metabonomic Analysis. Journal of Proteome Research, 2013, 12, 4393-4401.	3.7	76

#	Article	IF	Citations
19	Overexpression and knockout of miR-126 both promote leukemogenesis. Blood, 2015, 126, 2005-2015.	1.4	65
20	Integrated genomic analysis identifies deregulated JAK/STAT-MYC-biosynthesis axis in aggressive NK-cell leukemia. Cell Research, 2018, 28, 172-186.	12.0	62
21	Multicentre, randomised phase <scp>III</scp> study of the efficacy and safety of eltrombopag in Chinese patients with chronic immune thrombocytopenia. British Journal of Haematology, 2017, 176, 101-110.	2.5	55
22	High PARP-1 expression predicts poor survival in acute myeloid leukemia and PARP-1 inhibitor and SAHA-bendamustine hybrid inhibitor combination treatment synergistically enhances anti-tumor effects. EBioMedicine, 2018, 38, 47-56.	6.1	54
23	Eradication of Acute Myeloid Leukemia with FLT3 Ligandâ€“Targeted miR-150 Nanoparticles. Cancer Research, 2016, 76, 4470-4480.	0.9	48
24	Prognostic Value of Isocitrate Dehydrogenase Mutations in Myelodysplastic Syndromes: A Retrospective Cohort Study and Meta-Analysis. PLoS ONE, 2014, 9, e100206.	2.5	47
25	PBX3 and MEIS1 Cooperate in Hematopoietic Cells to Drive Acute Myeloid Leukemias Characterized by a Core Transcriptome of the MLL-Rearranged Disease. Cancer Research, 2016, 76, 619-629.	0.9	45
26	Targeted inhibition of STAT/TET1 axis as a therapeutic strategy for acute myeloid leukemia. Nature Communications, 2017, 8, 2099.	12.8	45
27	Egr-1 promotes hypoxia-induced autophagy to enhance chemo-resistance of hepatocellular carcinoma cells. Experimental Cell Research, 2016, 340, 62-70.	2.6	44
28	Mutations of Epigenetic Modifier Genes as a Poor Prognostic Factor in Acute Promyelocytic Leukemia Under Treatment With All-Trans Retinoic Acid and Arsenic Trioxide. EBioMedicine, 2015, 2, 563-571.	6.1	42
29	The MAGNOLIA Trial: Zanubrutinib, a Next-Generation Bruton Tyrosine Kinase Inhibitor, Demonstrates Safety and Efficacy in Relapsed/Refractory Marginal Zone Lymphoma. Clinical Cancer Research, 2021, 27, 6323-6332.	7.0	42
30	Homoharringtonine exhibits potent anti-tumor effect and modulates DNA epigenome in acute myeloid leukemia by targeting SP1/TET1/5hmC. Haematologica, 2020, 105, 148-160.	3.5	41
31	High IDH1 expression is associated with a poor prognosis in cytogenetically normal acute myeloid leukemia. International Journal of Cancer, 2015, 137, 1058-1065.	5.1	39
32	Evaluating frequency of PML-RARA mutations and conferring resistance to arsenic trioxide-based therapy in relapsed acute promyelocytic leukemia patients. Annals of Hematology, 2015, 94, 1829-1837.	1.8	38
33	Prognostic factors of patients with newly diagnosed acute promyelocytic leukemia treated with arsenic trioxide-based frontline therapy. Leukemia Research, 2015, 39, 938-944.	0.8	37
34	Worldwide cancer statistics of adolescents and young adults in 2019: aÂsystematic analysis of the Global Burden of Disease Study 2019. ESMO Open, 2021, 6, 100255.	4.5	37
35	Lysine-specific demethylase 1 mediates epidermal growth factor signaling to promote cell migration in ovarian cancer cells. Scientific Reports, 2015, 5, 15344.	3.3	36
36	Changes in Follicular Helper T Cells in Idiopathic Thrombocytopenic Purpura Patients. International Journal of Biological Sciences, 2015, 11, 220-229.	6.4	36

#	Article	IF	Citations
37	FoxM1-mediated RFC5 expression promotes temozolomide resistance. Cell Biology and Toxicology, 2017, 33, 527-537.	5.3	35
38	A proposal for a new staging system for extranodal natural killer T-cell lymphoma: a multicenter study from China and Asia Lymphoma Study Group. Leukemia, 2020, 34, 2243-2248.	7.2	35
39	Leukemia stem cell-bone marrow microenvironment interplay in acute myeloid leukemia development. Experimental Hematology and Oncology, 2021, 10, 39.	5.0	35
40	All-Trans Retinoic Acid plus Arsenic Trioxide versus All-Trans Retinoic Acid plus Chemotherapy for Newly Diagnosed Acute Promyelocytic Leukemia: A Meta-Analysis. PLoS ONE, 2016, 11, e0158760.	2.5	33
41	LSD1-mediated epigenetic modification contributes to ovarian cancer cell migration and invasion. Oncology Reports, 2016, 35, 3586-3592.	2.6	33
42	High Expression of TET1 Predicts Poor Survival in Cytogenetically Normal Acute Myeloid Leukemia From Two Cohorts. EBioMedicine, 2018, 28, 90-96.	6.1	33
43	A multicenter, randomized phase III trial of hetrombopag: a novel thrombopoietin receptor agonist for the treatment of immune thrombocytopenia. Journal of Hematology and Oncology, 2021, 14, 37.	17.0	33
44	Mutation status and burden can improve prognostic prediction of patients with lowerâ€risk myelodysplastic syndromes. Cancer Science, 2020, 111, 580-591.	3.9	33
45	Impact of TET2, SRSF2, ASXL1 and SETBP1 mutations on survival of patients with chronic myelomonocytic leukemia. Experimental Hematology and Oncology, 2015, 4, 14.	5.0	32
46	Ibrutinib versus rituximab in relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma: a randomized, openâ€label phase 3 study. Cancer Medicine, 2018, 7, 1043-1055.	2.8	32
47	Current views on the genetic landscape and management of variant acute promyelocytic leukemia. Biomarker Research, 2021, 9, 33.	6.8	30
48	Two-Year Follow-up of Investigator-Initiated Phase 1 Trials of the Safety and Efficacy of Fully Human Anti-Bcma CAR T Cells (CT053) in Relapsed/Refractory Multiple Myeloma. Blood, 2020, 136, 27-28.	1.4	28
49	Decitabine for Treatment of Myelodysplastic Syndromes in Chinese Patients: An Open-Label, Phase-3b Study. Advances in Therapy, 2015, 32, 1140-1159.	2.9	27
50	Epigenetic priming with decitabine followed by low-dose idarubicin/cytarabine has an increased anti-leukemic effect compared to traditional chemotherapy in high-risk myeloid neoplasms. Leukemia and Lymphoma, 2016, 57, 1311-1318.	1.3	27
51	Setd2 regulates quiescence and differentiation of adult hematopoietic stem cells by restricting RNA polymerase II elongation. Haematologica, 2018, 103, 1110-1123.	3.5	27
52	Cytokine profiles in patients with newly diagnosed multiple myeloma: Survival is associated with IL-6 and IL-17A levels. Cytokine, 2021, 138, 155358.	3.2	27
53	High efficacy of arsenic trioxide plus all-trans retinoic acid based induction and maintenance therapy in newly diagnosed acute promyelocytic leukemia. Leukemia Research, 2013, 37, 37-42.	0.8	26
54	Hyperthermia Selectively Destabilizes Oncogenic Fusion Proteins. Blood Cancer Discovery, 2021, 2, 388-401.	5.0	26

#	Article	IF	Citations
55	Circularly permuted TRAIL plus thalidomide and dexamethasone versus thalidomide and dexamethasone for relapsed/refractory multiple myeloma: a phase 2 study. Cancer Chemotherapy and Pharmacology, 2017, 79, 1141-1149.	2.3	25
56	The high NRF2 expression confers chemotherapy resistance partly through up-regulated DUSP1 in myelodysplastic syndromes. Haematologica, 2019, 104, 485-496.	3.5	25
57	Flumatinib versus Imatinib for Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia: A Phase III, Randomized, Open-label, Multi-center FESTnd Study. Clinical Cancer Research, 2021, 27, 70-77.	7.0	25
58	ERG11 Gene Mutations and MDR1 Upregulation Confer Pan-Azole Resistance in Candida tropicalis Causing Disseminated Candidiasis in an Acute Lymphoblastic Leukemia Patient on Posaconazole Prophylaxis. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	24
59	Effectivity of a modified Sanz risk model for early death prediction in patients with newly diagnosed acute promyelocytic leukemia. Annals of Hematology, 2017, 96, 1793-1800.	1.8	24
60	Low expression of ACLY associates with favorable prognosis in acute myeloid leukemia. Journal of Translational Medicine, 2019, 17, 149.	4.4	24
61	Effective gene-viral therapy of leukemia by a new fiber chimeric oncolytic adenovirus expressing TRAIL: in vitro and in vivo evaluation. Molecular Cancer Therapeutics, 2009, 8, 1387-1397.	4.1	23
62	MiR-362-5p as a novel prognostic predictor of cytogenetically normal acute myeloid leukemia. Journal of Translational Medicine, 2018, 16, 68.	4.4	23
63	Global, Regional, and National Burden of Chronic Myeloid Leukemia, 1990â€“2017: A Systematic Analysis for the Global Burden of Disease Study 2017. Frontiers in Oncology, 2020, 10, 580759.	2.8	23
64	Autophagy contributes to ING4-induced glioma cell death. Experimental Cell Research, 2013, 319, 1714-1723.	2.6	22
65	Longâ€term survival of acute promyelocytic leukaemia patients treated with arsenic and retinoic acid. British Journal of Haematology, 2016, 174, 820-822.	2.5	22
66	Current Treatment Patterns of Aplastic Anemia in China: A Prospective Cohort Registry Study. Acta Haematologica, 2019, 142, 162-170.	1.4	22
67	Prognostic impact of MYH9 expression on patients with acute myeloid leukemia. Oncotarget, 2017, 8, 156-163.	1.8	22
68	Geriatric nutritional risk index is not an independent predictor in patients with diffuse large B-cell lymphoma. Cancer Biomarkers, 2018, 21, 813-820.	1.7	21
69	Zanubrutinib monotherapy in relapsed/refractory mantle cell lymphoma: a pooled analysis of two clinical trials. Journal of Hematology and Oncology, 2021, 14, 167.	17.0	21
70	Nitrogen-doped carbon dots as multifunctional fluorescent probes. Journal of Nanoparticle Research, 2014, 16, 1.	1.9	20
71	Efficacy and predictive factors of venetoclax combined with azacitidine as salvage therapy in advanced acute myeloid leukemia patients: A multicenter retrospective study. Leukemia Research, 2020, 91, 106317.	0.8	19
72	A Phase II Trial of the Bruton Tyrosine-Kinase Inhibitor Zanubrutinib (BGB-3111) in Patients with Relapsed/Refractory WaldenstrÃ¶m Macroglobulinemia. Clinical Cancer Research, 2021, 27, 5492-5501.	7.0	19

#	Article	IF	Citations
73	Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Chinese Patients with Relapsed or Refractory Multiple Myeloma: Phase 3 LEPUS (MMY3009) Study. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, e699-e709.	0.4	19
74	Efficacy and prognostic factors of imatinib plus CALLG2008 protocol in adult patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Frontiers of Medicine, 2017, 11, 229-238.	3.4	18
75	Isocitrate dehydrogenase 2 mutations correlate with leukemic transformation and are predicted by 2-hydroxyglutarate in myelodysplastic syndromes. Journal of Cancer Research and Clinical Oncology, 2018, 144, 1037-1047.	2.5	18
76	A phase 3 study of rituximab biosimilar HLX01 in patients with diffuse large B-cell lymphoma. Journal of Hematology and Oncology, 2020, 13, 38.	17.0	18
77	Transcriptome-wide subtyping of pediatric and adult T cell acute lymphoblastic leukemia in an international study of 707 cases. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, e2120787119.	7.1	18
78	Efficacy and safety of eltrombopag in Chinese patients with chronic immune thrombocytopenia: stage 2 results from a multicenter phase III study. Platelets, 2022, 33, 82-88.	2.3	17
79	Hyaluronic Acid-Functionalized Gadolinium Oxide Nanoparticles for Magnetic Resonance Imaging-Guided Radiotherapy of Tumors. Nanoscale Research Letters, 2020, 15, 94.	5.7	17
80	Low-dose cytarabine, aclarubicin and granulocyte colony-stimulating factor priming regimen versus idarubicin plus cytarabine regimen as induction therapy for older patients with acute myeloid leukemia. Leukemia and Lymphoma, 2015, 56, 1691-1697.	1.3	16
81	Abivertinib, a novel BTK inhibitor: Anti-Leukemia effects and synergistic efficacy with homoharringtonine in acute myeloid leukemia. Cancer Letters, 2019, 461, 132-143.	7.2	16
82	Apigenin and Abivertinib, a novel BTK inhibitor synergize to inhibit diffuse large B-cell lymphoma in vivo and vitro. Journal of Cancer, 2020, 11, 2123-2132.	2.5	16
83	New perspectives in genetics and targeted therapy for blastic plasmacytoid dendritic cell neoplasm. Critical Reviews in Oncology/Hematology, 2020, 149, 102928.	4.4	16
84	Clinicopathological study on peripheral T-cell non-Hodgkin lymphoma with bone marrow involvement: a retrospective analysis from China. International Journal of Hematology, 2009, 90, 303-310.	1.6	15
85	Plasma exosome-derived microRNA-532 as a novel predictor for acute myeloid leukemia. Cancer Biomarkers, 2020, 28, 151-158.	1.7	15
86	<scp>CDKN2A</scp> deletions are associated with poor outcomes in 101 adults with Tâ€cell acute lymphoblastic leukemia. American Journal of Hematology, 2021, 96, 312-319.	4.1	15
87	The combination effect of homoharringtonine and ibrutinib on FLT3-ITD mutant acute myeloid leukemia. Oncotarget, 2017, 8, 12764-12774.	1.8	15
88	Analysis of clinical characteristics and prognostic factors of multiple myeloma: a retrospective single-center study of 787 cases. Hematology, 2017, 22, 1-5.	1.5	14
89	Prognostic significance of huntingtin interacting protein 1 expression on patients with acute myeloid leukemia. Scientific Reports, 2017, 7, 45960.	3.3	14
90	Relapsed/refractory early T-cell precursor acute lymphoblastic leukemia was salvaged by venetoclax plus HAG regimen. Annals of Hematology, 2020, 99, 395-397.	1.8	14

#	Article	IF	Citations
91	The specific distribution pattern of IKZF1 mutation in acute myeloid leukemia. Journal of Hematology and Oncology, 2020, 13, 140.	17.0	14
92	Comparison of Early T-Cell Precursor and Non-ETP Subtypes Among 122 Chinese Adults With Acute Lymphoblastic Leukemia. Frontiers in Oncology, 2020, 10, 1423.	2.8	14
93	Early Death and Survival of Patients With Acute Promyelocytic Leukemia in ATRA Plus Arsenic Era: A Population-Based Study. Frontiers in Oncology, 2021, 11, 762653.	2.8	14
94	Venetoclax-ponatinib for T315I/compound-mutated Ph+ acute lymphoblastic leukemia. Blood Cancer Journal, 2022, 12, 20.	6.2	14
95	TET2 mutations were predictive of inferior prognosis in the presence of ASXL1 mutations in patients with chronic myelomonocytic leukemia. Stem Cell Investigation, 2016, 3, 50-50.	3.0	13
96	PP2A inhibition from LB100 therapy enhances daunorubicin cytotoxicity in secondary acute myeloid leukemia via miR-181b-1 upregulation. Scientific Reports, 2017, 7, 2894.	3.3	13
97	RARÎ³-rearrangements resemble acute promyelocytic leukemia and benefit from 3â€‰+â€‰7 regimen. Leukemia and Lymphoma, 2019, 60, 1831-1834.	1.3	13
98	Treatment-induced arteriolar revascularization and miR-126 enhancement in bone marrow niche protect leukemic stem cells in AML. Journal of Hematology and Oncology, 2021, 14, 122.	17.0	13
99	Efficacy and Safety of Zanubrutinib in Patients with Relapsed/Refractory Marginal Zone Lymphoma: Initial Results of the MAGNOLIA (BGB-3111-214) Trial. Blood, 2020, 136, 28-30.	1.4	13
100	Long-term efficacy of low-dose all-trans retinoic acid plus minimal chemotherapy induction followed by the addition of intravenous arsenic trioxide post-remission therapy in newly diagnosed acute promyelocytic leukaemia. Hematological Oncology, 2014, 32, 40-46.	1.7	12
101	A Multinational, Open-Label Phase 2 Study Of Ruxolitinib In Asian Patients (Pts) With Primary Myelofibrosis (PMF), Postâ€“Polycythemia Vera MF (PPV-MF), Or Postâ€“Essential Thrombocythemia MF (PET-MF). Blood, 2013, 122, 4086-4086.	1.4	12
102	A Multi-Center, Real-World Study of Chidamide for Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas in China. Frontiers in Oncology, 2021, 11, 750323.	2.8	12
103	Tea consumption reduces the risk of de novo myelodysplastic syndromes. Leukemia Research, 2015, 39, 164-169.	0.8	11
104	Clinical Significance of Prognostic Nutritional Index for Patients with Diffuse Large B-cell Lymphoma. Nutrition and Cancer, 2019, 71, 569-574.	2.0	11
105	miR-550-1 functions as a tumor suppressor in acute myeloid leukemia via the hippo signaling pathway. International Journal of Biological Sciences, 2020, 16, 2853-2867.	6.4	11
106	Development and validation of a novel circular RNA as an independent prognostic factor in acute myeloid leukemia. BMC Medicine, 2021, 19, 28.	5.5	11
107	Inhibition of CPT1a as a prognostic marker can synergistically enhance the antileukemic activity of ABT199. Journal of Translational Medicine, 2021, 19, 181.	4.4	11
108	Pooled Analysis of Safety Data from Clinical Trials of Orelabrutinib Monotherapy in Hematologic Malignancies. Blood, 2020, 136, 43-43.	1.4	11

#	Article	IF	Citations
109	Camrelizumab for relapsed or refractory classical Hodgkin lymphoma: extended followâ€up of the multicenter, singleâ€arm, phase 2 study. International Journal of Cancer, 2021, , .	5.1	11
110	Early BCR-ABL1 decline in imatinib-treated patients with chronic myeloid leukemia: results from a multicenter study of the Chinese CML alliance. Blood Cancer Journal, 2018, 8, 61.	6.2	10
111	Targeting cell membrane HDM2: A novel therapeutic approach for acute myeloid leukemia. Leukemia, 2020, 34, 75-86.	7.2	10
112	Venetoclax and arsenic showed synergistic antiâ€leukemia activity in vitro and in vivo for acute myeloid leukemia with the NPM1 mutation. American Journal of Hematology, 2020, 95, E55-E57.	4.1	10
113	Identification of a novel <scp>NUP98â€RARA</scp> fusion transcript as the 14th variant of acute promyelocytic leukemia. American Journal of Hematology, 2020, 95, E184-E186.	4.1	10
114	MAP4K1 functions as a tumor promotor and drug mediator for AML via modulation of DNA damage/repair system and MAPK pathway. EBioMedicine, 2021, 69, 103441.	6.1	10
115	Fatal hemorrhagic pneumonia in patients with hematologic diseases and Stenotrophomonas maltophilia bacteremia: a retrospective study. BMC Infectious Diseases, 2021, 21, 723.	2.9	10
116	Green tea consumption and glutathione S-transferases genetic polymorphisms on the risk of adult leukemia. European Journal of Nutrition, 2017, 56, 603-612.	3.9	9
117	Promising efficacy of novel BTK inhibitor AC0010 in mantle cell lymphoma. Journal of Cancer Research and Clinical Oncology, 2018, 144, 697-706.	2.5	9
118	Improved longâ€term survival in all Sanz risk patients of newly diagnosed acute promyelocytic leukemia treated with a combination of retinoic acid and arsenic trioxideâ€based frontâ€line therapy. Hematological Oncology, 2018, 36, 584-590.	1.7	9
119	Oral Realgar-Indigo Naturalis Formula Plus Retinoic Acid for Acute Promyelocytic Leukemia. Frontiers in Oncology, 2020, 10, 597601.	2.8	9
120	Construction of a novel ferroptosis-related gene signature for predicting prognosis and immune microenvironment in acute myeloid leukemia. Bosnian Journal of Basic Medical Sciences, 2021, , .	1.0	9
121	Venetoclax for arsenicâ€resistant acute promyelocytic leukaemia. British Journal of Haematology, 2022, 197, .	2.5	9
122	Downregulation of hTERT: An Important As2O3 Induced Mechanism of Apoptosis in Myelodysplastic Syndrome. PLoS ONE, 2014, 9, e113199.	2.5	8
123	Hypofibrinogenemia as a clue in the presumptive diagnosis of acute promyelocytic leukemia. Leukemia Research, 2016, 50, 11-16.	0.8	8
124	Alcohol consumption and risk of myelodysplastic syndromes: a caseâ€“control study. Cancer Causes and Control, 2016, 27, 209-216.	1.8	8
125	Inactivation of EGFR/AKT signaling enhances TSA-induced ovarian cancer cell differentiation. Oncology Reports, 2017, 37, 2891-2896.	2.6	8
126	ARID1A mutation in blastic plasmacytoid dendritic cell neoplasm. Haematologica, 2017, 102, e470-e472.	3.5	8

#	Article	IF	Citations
127	Inhibition of lysineâ€specific demethylase 1 prevents proliferation and mediates cisplatin sensitivity in ovarian cancer cells. Oncology Letters, 2018, 15, 9025-9032.	1.8	8
128	Analysis of clinical and molecular features of MDS patients with complex karyotype in China. Blood Cells, Molecules, and Diseases, 2019, 75, 13-19.	1.4	8
129	Minimal residual disease level determined by flow cytometry provides reliable risk stratification in adults with Tâ€cell acute lymphoblastic leukaemia. British Journal of Haematology, 2021, 193, 1096-1104.	2.5	8
130	Clinical Features and Prognostic Significance of NOTCH1 Mutations in Diffuse Large B-Cell Lymphoma. Frontiers in Oncology, 2021, 11, 746577.	2.8	8
131	Impact of Chemotherapy Delay on Overall Survival for AML with IDH1/2 Mutations: A Study in Adult Chinese Patients. PLoS ONE, 2015, 10, e0140622.	2.5	7
132	Diagnosis and management of acquired thrombotic thrombocytopenic purpura in southeast China: a single center experience of 60 cases. Frontiers of Medicine, 2016, 10, 430-436.	3.4	7
133	Decitabine priming prior to low-dose chemotherapy improves patient outcomes in myelodysplastic syndromes-RAEB: a retrospective analysis vs. chemotherapy alone. Journal of Cancer Research and Clinical Oncology, 2017, 143, 873-882.	2.5	7
134	Salvage therapy with lenalidomide containing regimen for relapsed/refractory Castleman disease: a report of three cases. Frontiers of Medicine, 2017, 11, 287-292.	3.4	7
135	Utility of CT assessment in hematology patients with invasive aspergillosis: a post-hoc analysis of phase 3 data. BMC Infectious Diseases, 2019, 19, 471.	2.9	7
136	Aberrant expression of NLRP3, NLRC4 and NLRP6 inflammasomes in patients with primary immune thrombocytopenia. Thrombosis Research, 2019, 176, 101-103.	1.7	7
137	Intracerebral Hemorrhage as the Initial Presentation of Chronic Myeloid Leukemia: A Case Report and Review of the Literature. Frontiers in Neurology, 2020, 11, 571576.	2.4	7
138	Increased Serum Level of Interleukin-10 Predicts Poor Survival and Early Recurrence in Patients With Peripheral T-Cell Lymphomas. Frontiers in Oncology, 2020, 10, 584261.	2.8	7
139	Sorafenib in combination with low-dose-homoharringtonine as a salvage therapy in primary refractory FLT3-ITD-positive AML: a case report and review of literature. International Journal of Clinical and Experimental Medicine, 2015, 8, 19891-4.	1.3	7
140	A real-world study of infectious complications of venetoclax combined with decitabine or azacitidine in adult acute myeloid leukemia. Supportive Care in Cancer, 2022, 30, 7031-7038.	2.2	7
141	Homoharringtonine is synergistically lethal with BCL-2 inhibitor APG-2575 in acute myeloid leukemia. Journal of Translational Medicine, 2022, 20, .	4.4	7
142	The change of nuclear LC3 distribution in acute myeloid leukemia cells. Experimental Cell Research, 2018, 369, 69-79.	2.6	6
143	Leukemia cutis with IDH1, DNMT3A and NRAS mutations conferring resistance to venetoclax plus 5-azacytidine in refractory AML. Biomarker Research, 2020, 8, 65.	6.8	6
144	CAG regimen for refractory or relapsed adult Tâ€cell acute lymphoblastic leukemia: A retrospective, multicenter, cohort study. Cancer Medicine, 2020, 9, 5327-5334.	2.8	6

#	Article	IF	Citations
145	The relationship between consumption of nitrite or nitrate and risk of non-Hodgkin lymphoma. Scientific Reports, 2020, 10, 551.	3.3	6
146	Realâ€world data of chronic myelomonocytic leukemia: A chinese singleâ€center retrospective study. Cancer Medicine, 2021, 10, 1715-1725.	2.8	6
147	Effect of Eltrombopag on Platelet Response and Safety Results in Chinese Adults with Chronic ITP-Primary Result of a Phase III Study. Blood, 2014, 124, 1464-1464.	1.4	6
148	Long-Term Safety of Dasatinib in Chinese Chronic Phase Chronic Myeloid Leukemia Patients with Imatinib-Resistance or -Intolerance: Results from a 6-Year Follow-up of a Multicenter Phase II Study. Blood, 2016, 128, 1928-1928.	1.4	6
149	Dose tapering to withdrawal stage and longâ€term efficacy and safety of hetrombopag for the treatment of immune thrombocytopenia: Results from an openâ€label extension study. Journal of Thrombosis and Haemostasis, 2022, 20, 716-728.	3.8	6
150	Abivertinib inhibits megakaryocyte differentiation and platelet biogenesis. Frontiers of Medicine, 2021, , 1.	3.4	6
151	Predictive values of mutational variant allele frequency in overall survival and leukemic progression of myelodysplastic syndromes. Journal of Cancer Research and Clinical Oncology, 2022, 148, 845-856.	2.5	6
152	Antitumor activity and drug interactions of proteasome inhibitor Bortezomib in human high-risk myelodysplastic syndrome cells. International Journal of Hematology, 2011, 93, 482-493.	1.6	5
153	RIG-G inhibits the proliferation of NB4 cells and propels ATRA-induced differentiation of APL cells. Leukemia Research, 2016, 40, 83-89.	0.8	5
154	Polymorphisms of 5,10-methylenetetrahydrofolate reductase and thymidylate synthase, dietary folate intake, and the risk of leukemia in adults. Tumor Biology, 2016, 37, 3265-3275.	1.8	5
155	Prognostic utility of six mutated genes for older patients with acute myeloid leukemia. International Journal of Cancer, 2018, 142, 1664-1670.	5.1	5
156	Efficacy and safety of early switching to an outpatient therapy model using oral arsenic plus retinoic acid based-regimen in newly diagnosed acute promyelocytic leukemia. Leukemia Research, 2019, 83, 106168.	0.8	5
157	Four-year follow-up of patients with imatinib-resistant or intolerant chronic myeloid leukemia receiving dasatinib: efficacy and safety. Frontiers of Medicine, 2019, 13, 344-353.	3.4	5
158	Abivertinib synergistically strengthens the antiâ€leukemia activity of venetoclax in acute myeloid leukemia in a BTKâ€dependent manner. Molecular Oncology, 2020, 14, 2560-2573.	4.6	5
159	Clinical features and treatment of 7 Chinese TAFRO syndromes from 96 de novo Castleman diseases: a 10-year retrospective study. Journal of Cancer Research and Clinical Oncology, 2020, 146, 357-365.	2.5	5
160	An oral, chemotherapyâ€free regimen (dasatinib plus prednisone) as induction and consolidation for adult patients with Philadelphia chromosomeâ€positive acute lymphoblastic leukaemia. British Journal of Haematology, 2020, 189, e231-e234.	2.5	5
161	A study of carfilzomib and dexamethasone in patients with relapsed and refractory multiple myeloma in China. International Journal of Hematology, 2021, 113, 422-429.	1.6	5
162	The first report of complete remission following treatment with venetoclax plus prednisone in elderly patients with Philadelphia chromosome-negative acute lymphoblastic leukemia. Annals of Hematology, 2022, 101, 1141-1144.	1.8	5

#	Article	IF	Citations
163	The value of a new prognostic model developed by lymphocyte-monocyte ratio and platelet-monocyte ratio in peripheral T-cell lymphoma. Cancer Cell International, 2021, 21, 573.	4.1	5
164	Distinct outcomes, ABL1 mutation profile, and transcriptome features between p190 and p210 transcripts in adult Philadelphia-positive acute lymphoblastic leukemia in the TKI era. Experimental Hematology and Oncology, 2022, 11, 13.	5.0	5
165	A novel alkylating deacetylase inhibitor molecule EDO-S101 in combination with cytarabine synergistically enhances apoptosis of acute myeloid leukemia cells. Medical Oncology, 2019, 36, 77.	2.5	4
166	Clinical characteristics and prognostic values of 1p32.3 deletion detected through fluorescence in situ hybridization in patients with newly diagnosed multiple myeloma: a single-center study in China. Frontiers of Medicine, 2020, 14, 327-334.	3.4	4
167	TP53 mutations are associated with very complex karyotype and suggest poor prognosis in newly diagnosed myelodysplastic syndrome patients with monosomal karyotype. Asia-Pacific Journal of Clinical Oncology, 2020, 16, 172-179.	1.1	4
168	Ibrutinib Suppresses Early Megakaryopoiesis but Enhances Proplatelet Formation. Thrombosis and Haemostasis, 2021, 121, 192-205.	3.4	4
169	Clinical significance of cytogenetic and molecular genetic abnormalities in 634 Chinese patients with myelodysplastic syndromes. Cancer Medicine, 2021, 10, 1759-1771.	2.8	4
170	Bortezomib in combination with fludarabine plus cyclophosphamide for patients with relapsed or refractory mantle-cell lymphoma: results of the LYM-4003 study. Annals of Hematology, 2021, 100, 2961-2968.	1.8	4
171	CYP3A inhibitors and impact of these agents on outcomes in patients with acute myeloid leukemia treated with venetoclax plus azacitidine on the VIALE-A study. Blood, 2020, 136, 50-52.	1.4	4
172	Targeting miRâ€126 disrupts maintenance of myelodysplastic syndrome stem and progenitor cells. Clinical and Translational Medicine, 2021, 11, e610.	4.0	4
173	Coexistence of multiple myeloma and clear cell renal cell carcinoma: a case report and review of literature. International Journal of Clinical and Experimental Pathology, 2015, 8, 7627-30.	0.5	4
174	Ex Vivo Chemosensitivity Profiling of Acute Myeloid Leukemia and Its Correlation With Clinical Response and Outcome to Chemotherapy. Frontiers in Oncology, 2021, 11, 793773.	2.8	4
175	Modified cladribine, cytarabine, and G-CSF as a salvage regimen in patients with relapsed/refractory acute myeloid leukemia: a bridge to myeloablative allogeneic hematopoietic stem cell transplantation. Annals of Hematology, 2019, 98, 2073-2080.	1.8	3
176	Decitabine improves overall survival in myelodysplastic syndromes-RAEB patients aged â‰¥60â€¯years and has lower toxicities: Comparison with low-dose chemotherapy. Blood Cells, Molecules, and Diseases, 2019, 77, 88-94.	1.4	3
177	Decitabine for myelodysplastic syndromes: dose comparison in a real world clinical setting. Leukemia and Lymphoma, 2019, 60, 1731-1739.	1.3	3
178	Characteristics of chemotherapy-induced diabetes mellitus in acute lymphoblastic leukemia patients. Journal of Zhejiang University: Science B, 2020, 21, 740-744.	2.8	3
179	Epigenetic priming with decitabine followed by low dose idarubicin and cytarabine in acute myeloid leukemia evolving from myelodysplastic syndromes and higherâ€risk myelodysplastic syndromes: a prospective multicenter singleâ€arm trial. Hematological Oncology, 2020, 38, 531-540.	1.7	3
180	<scp>PMLâ€RARA</scp> monitoring in newly diagnosed acute promyelocytic leukemia treated with an entirely oral chemotherapyâ€free postremission approach: A multiple institution experience. Hematological Oncology, 2020, 38, 618-621.	1.7	3

#	Article	IF	Citations
181	Mutational analysis in different foci revealing the clonal evolution of blastic plasmacytoid dendritic cell neoplasm. Leukemia and Lymphoma, 2021, 62, 988-991.	1.3	3
182	Adolescents experienced more treatment failure than children with chronic myeloid leukemia receiving imatinib as frontline therapy: a retrospective multicenter study. Annals of Hematology, 2021, 100, 2215-2228.	1.8	3
183	Significance of initial, interim and end-of-therapy 18F-FDG PET/CT for predicting transformation risk in follicular lymphoma. Cancer Cell International, 2021, 21, 394.	4.1	3
184	Health-related quality of life in children with chronic myeloid leukemia in the chronic phase. Journal of Cancer Research and Clinical Oncology, 2022, 148, 341-350.	2.5	3
185	High-dose methotrexate plus temozolomide as a salvage treatment in metastatic central nervous system Lymphoma: two cases report and review of literature. International Journal of Clinical and Experimental Medicine, 2015, 8, 8222-5.	1.3	3
186	Safety and Efficacy of the Bruton Tyrosine Kinase Inhibitor Zanubrutinib (BGB-3111) in Patients with WaldenstrC6m Macroglobulinemia from a Phase 2 Trial. Blood, 2020, 136, 42-43.	1.4	3
187	A Predictor Combining Clinical and Genetic Factors for AML1-ETO Leukemia Patients. Frontiers in Oncology, 2021, 11, 783114.	2.8	3
188	Antitumor activity of CDA-II, a urinary preparation, on human multiple myeloma cell lines via the mitochondrial pathway. Molecular Medicine Reports, 2014, 9, 1025-1031.	2.4	2
189	Dietary isoflavone intake is associated with a reduced risk of myelodysplastic syndromes. British Journal of Nutrition, 2015, 114, 2110-2115.	2.3	2
190	A case of multiple recurrence of Clostridium difficile infection with severe hematochezia in an immunocompromised host. Anaerobe, 2016, 42, 31-32.	2.1	2
191	Caspofungin Treatment for Pulmonary Invasive Fungal Disease in Hematology Patients: A Retrospective Study in a Clinical Practice Setting in China. Clinical Therapeutics, 2017, 39, 1758-1768.	2.5	2
192	Clinical and biological characteristics of acute myeloid leukemia with 20â€“29% blasts: a retrospective single-center study. Leukemia and Lymphoma, 2019, 60, 1136-1145.	1.3	2
193	Co-existence of myeloproliferative neoplasias and Î²-thalassemia with IVS-2-654 mutationâ€”a case report. Translational Cancer Research, 2020, 9, 2069-2073.	1.0	2
194	Coagulation profile in newly diagnosed T-cell acute lymphoblastic leukemia. Thrombosis Research, 2021, 203, 69-71.	1.7	2
195	Case Report: The First Report of NUP214-ABL1 Fusion Gene in Acute Myeloid Leukemia Patient Detected by Next-Generation Sequencing. Frontiers in Oncology, 2021, 11, 706798.	2.8	2
196	Efficacy of Caspofungin in Unclassified Invasive Fungal Infection Cases: A Retrospective Analysis of Patients with Hematological Malignancies in China. Medical Science Monitor, 2018, 24, 5258-5270.	1.1	2
197	Impact of mutational variant allele frequency on prognosis in myelodysplastic syndromes. American Journal of Cancer Research, 2020, 10, 4476-4487.	1.4	2
198	A Phase 1 Study to Evaluate the Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Lisaftoclax (APG-2575), a Novel BCL-2 Inhibitor (BCL-2i), in Patients (pts) with Certain Relapsed or Refractory (R/R) Hematologic Malignancies (HMs). Blood, 2021, 138, 3730-3730.	1.4	2

#	Article	IF	Citations
199	Results from a Phase 2 Study of a Novel Janus Kinase Inhibitor in Treatment of Patients with Myelofibrosis. Blood, 2021, 138, 387-387.	1.4	2
200	Long-term use of lenalidomide and low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma: MM-024 Extended Access Program. BMC Cancer, 2016, 16, 46.	2.6	1
201	Overexpression of musashi2 is possibly associated with chemoresistance in T-cell acute lymphoblastic leukemia. Leukemia and Lymphoma, 2016, 57, 467-469.	1.3	1
202	ASXL2 mutation is recurrent in non-de novo AML1-ETO-negative acute myeloid leukemia. Annals of Hematology, 2019, 98, 2621-2623.	1.8	1
203	Mutation Status and Burden Can Improve Prognostic Prediction of Patients with Lower-Risk Myelodysplastic Syndromes. Blood, 2019, 134, 3008-3008.	1.4	1
204	Preliminary Results from a Phase I Study of SHC014748M in Patients with Relapsed or Refractory Indolent B-Cell Lymphomas. Blood, 2019, 134, 4000-4000.	1.4	1
205	High IDH1 Expression Is Associated with a Poor Prognosis in Cytogenetically Normal Acute Myeloid Leukemia. Blood, 2014, 124, 5314-5314.	1.4	1
206	Long-Term Efficacy of Low-Dose All-Trans Retinoic Acid Plus Individually Adapted Chemotherapy Induction Followed by Arsenic Trioxide Based Post-Remission Therapy in Adults with Newly Diagnosed Acute Promyelocytic Leukemia. Blood, 2012, 120, 1480-1480.	1.4	1
207	Overexpression and Knockout of Mir-126 Both Promote Leukemogenesis through Targeting Distinct Gene Signaling. Blood, 2015, 126, 3667-3667.	1.4	1
208	A case report for fatal Churg-Strauss syndrome complications: first reported death due to rapid progression of prominently huge hepatic capsular hematoma and multi-system organ hemorrhage. International Journal of Clinical and Experimental Medicine, 2014, 7, 3703-6.	1.3	1
209	Successful treatment of a case of acute myeloid leukemia following Langerhans cell histiocytosis in an adolescent: a case report and review of the literature. International Journal of Clinical and Experimental Medicine, 2015, 8, 3024-6.	1.3	1
210	A novel prognostic scoring model for newly diagnosed FLT3-ITD-positive acute myeloid leukemia. American Journal of Cancer Research, 2020, 10, 4527-4537.	1.4	1
211	Combination of Decitabine and ATRA in Newly Diagnosed Myelodysplastic Syndromes Subtype EB-Interim Analysis of a Multicenter, Randomized, Open-Label Trial. Blood, 2021, 138, 539-539.	1.4	1
212	Ruxolitinib Combined with Dexamethasone in Adult Patients with Secondary HLHï¼ša Single-Centre Pilot Trial. Blood, 2021, 138, 198-198.	1.4	1
213	A rare case of co-existent aggressive natural killer cell and acute monocytic leukemia with cytomegalovirus infection. International Journal of Hematology, 2008, 87, 553-556.	1.6	0
214	An open-label study of pegylated liposomal doxorubicin, vincristine, and reduced-dose dexamethasone combination therapy in newly diagnosed multiple myeloma patients in the Chinese population. Clinical Oncology and Cancer Research, 2009, 6, 394-400.	0.1	0
215	Identification of an IRF-1 splicing transcript in APL cells sharing similar transactivation activity of the full length one. Gene, 2017, 605, 108-113.	2.2	0
216	Insert restriction enzyme cutting-free cloning strategy for expression plasmid construction. Biotechnology and Biotechnological Equipment, 2017, 31, 1033-1039.	1.3	0

#	Article	IF	Citations
217	IDH1^{R132S}â€mutated acute lymphoblastic leukaemia resembles Burkitt lymphoma/leukaemia via activating MYC. British Journal of Haematology, 2021, 192, e44-e47.	2.5	0
218	Cytogenetic Abnormalities Predict Disease Progression in Primary Myelodysplastic Syndrome: A Multicentric Study in 508 Chinese Patients.. Blood, 2004, 104, 1451-1451.	1.4	0
219	Detection of Aspergillus Species in Blood of Malignant Hemotopoietic Tumor Patients by Two-Step PCR.. Blood, 2005, 106, 4626-4626.	1.4	0
220	MicroRNA Expression Signatures Accurately Discriminate Acute Lymphoblastic Leukemia from Acute Myeloid Leukemia.. Blood, 2007, 110, 231-231.	1.4	0
221	Clinical Characteristics of T-Cell Lymphoma Associated Hemophagocytic Syndrome: Comparison of T-Cell Lymphoma with and without Hemophagocytic Syndrome.. Blood, 2007, 110, 3576-3576.	1.4	0
222	MicroRNA Expression Profiles in Acute Myeloid Leukemia with Common Translocations.. Blood, 2007, 110, 3181-3181.	1.4	0
223	An Open-Label Study of Pegylated Liposomal Doxorubicin, Vincristine and Reduced-Dose Dexamethasone Combination Therapy in Newly Diagnosed Multiple Myeloma Patients in Chinese Population.. Blood, 2007, 110, 4816-4816.	1.4	0
224	A Clinical Study of Bortezomib in Combination with Dexamethasone and/or Doxorubibcin for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma. Blood, 2008, 112, 5216-5216.	1.4	0
225	Antitumor Activity of Human Urine Extract Cda-2 against Multiple Myeloma Cell Lines Via PI3K/Akt Signaling Pathway in a Caspase-3-Dependent Manner. Blood, 2008, 112, 5174-5174.	1.4	0
226	Apoptosis Was Induced by Casticin in Acute Myelocytic Leukemia Cells. Blood, 2008, 112, 3991-3991.	1.4	0
227	Expression of the Hypoxia-Inducible Factors In the AML and MDS: Is Not Associated with the Von Hippel-Lindau Gene. Blood, 2010, 116, 5114-5114.	1.4	0
228	Synergistic Depression of Wnt Pathway by Sequential Combination of Decitabine and Idarubicin in Human Myeloid Leukemic Cell Lines,. Blood, 2011, 118, 3628-3628.	1.4	0
229	Cytogenetic Analysis of 1863 Chineses Patients with Chronic Myeloid Leukemia. Blood, 2011, 118, 4888-4888.	1.4	0
230	A Multicenter, Randomized, Open-Label Study to Evaluate Safety and Efficacy of Posaconazole Vs Fluconazole in the Prophylaxis of Invasive Fungal Infection in a Chinese Population. Blood, 2011, 118, 4916-4916.	1.4	0
231	Phase 2 Study of Dasatinib in Chinese Patients (Pts) with Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) or Advanced Phase Who Are Resistant to or Intolerant of Imatinib (IM). Blood, 2011, 118, 4434-4434.	1.4	0
232	High Musashi-2 Expression Is an Unfavorable Prognostic Factor in Adult B-Cell Acute Lymphoblastic Leukemia.. Blood, 2012, 120, 2508-2508.	1.4	0
233	Serum 2-Hydroxyglutarate Level Is a Prognostic Marker in Acute Myeloid Leukemia. Blood, 2012, 120, 1433-1433.	1.4	0
234	Low-Dose Uroacitides(CDA-II) Downregulates Telomerase Activity and Inhibits Proliferation in the Telomerase-Expressing Maliganant Cell Lines Through Inactivation of Akt Signaling Pathway. Blood, 2012, 120, 4920-4920.	1.4	0

#	Article	IF	Citations
235	The MM-021 Trial Of Lenalidomide Plus Low-Dose Dexamethasone In Chinese Patients With Relapsed and Refractory Multiple Myeloma: Impact Of Prior Therapies On Efficacy and Safety. Blood, 2013, 122, 3227-3227.	1.4	0
236	MNK1 Inhibitor CGP57380 Overcomes the Activation of eIF4E Induced By mTORC1 Inhibitor: The Mechanism of Synergic Killing on T-ALL Cells. Blood, 2014, 124, 5215-5215.	1.4	0
237	Long-Term Use of Lenalidomide Plus Low-Dose Dexamethasone (Rd) in Chinese Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): MM-024 Expanded Access Program (EAP). Blood, 2014, 124, 5737-5737.	1.4	0
238	Identification of TET1âŠ£miR-22âŠ£CREB-MYC Signaling Reveals Potent Tumor-Suppressor Role of Mir-22 in Acute Myeloid Leukemia. Blood, 2014, 124, 886-886.	1.4	0
239	a Proposal for a New Staging System of Extranodal Natural Killer T-cell Lymphoma, Nasal-Type: a Multicenter Study of Chinese Southwest Oncology Group (CSWOG). Blood, 2014, 124, 4444-4444.	1.4	0
240	Interim Results of a Multi-Center Observational Study of Current Treatment Patterns for Patients with Severe Aplastic Anemia (SAA), Very Severe Aplastic Anemia (VSAA) and Transfusion-Dependent Non-Severe Aplastic Anemia (TD-NSAA) in China. Blood, 2015, 126, 4505-4505.	1.4	0
241	Alox5 Functions As Both Tumor Suppressor and Drug Sensitizer in AML. Blood, 2016, 128, 2851-2851.	1.4	0
242	Retrospective Study Evaluating Hematological Remission Rates and Survival in Chinese Adults with Relapsed or Refractory (r/r) Philadelphia Chromosome Negative (Ph-) B-Precursor Acute Lymphoblastic Leukemia (ALL). Blood, 2016, 128, 5198-5198.	1.4	0
243	The Combination Effect of Homoharringtonine and Ibrutinib on FLT3-ITD Mutant Acute Myeloid Leukemia. Blood, 2016, 128, 5225-5225.	1.4	0
244	SETD2, a H3K36 Lysine Methyltransferase, Is Essential for Adult Normal Hematopoiesis and Leukemia Stem Cells. Blood, 2016, 128, 1055-1055.	1.4	0
245	AC0010, a Novel BTK Inhibitor, Exerts Anti-Leukemia Effects and Synergizes the Efficiency of Homoharringtonine in AML. Blood, 2018, 132, 5153-5153.	1.4	0
246	High PARP-1 expression Predicts Poor Survival in Acute Myeloid Leukemia and PARP-1 Inhibitor and SAHA-Bendamustine Hybrid Inhibitor Combination Treatment Synergistically Enhances Anti-Tumor Effects. Blood, 2018, 132, 5252-5252.	1.4	0
247	Multidimensional Study on the Prognostic Factors of Acute Myeloid Leukemia Patients with FLT3-ITD mutations Based on the Next-Generation Sequencing Platform. Blood, 2018, 132, 5281-5281.	1.4	0
248	Overall Survival (OS) Benefit of Oral Ixazomib in Combination with Lenalidomide and Dexamethasone (IRd) Vs Lenalidomide and Dexamethasone (Rd) in Asian Patients (pts) with Relapsed and/or Refractory Multiple Myeloma (RRMM): Pooled-Analysis from the Tourmaline-MM1 and the China Continuation Studies. Blood, 2018, 132, 5637-5637.	1.4	0
249	R-2HG/KDM2B/RIPK1 Signaling Mediates Necroptosis in Myelodysplastic Syndromes. Blood, 2019, 134, 5049-5049.	1.4	0
250	Efficacy and Safety of Generic Imatinib in Chronic Phase of Chronic Myeloid Leukemia (CP-CML): Experience from a Multi-Center in China. Blood, 2019, 134, 5914-5914.	1.4	0
251	Targeting MiR-126 Blocks Progression of Myelodysplastic Syndrome and Transformation into Acute Myeloid Leukemia. Blood, 2019, 134, 1707-1707.	1.4	0
252	A Novel Role for Malate Dehydrogenase 1 in Acute Myeloid Leukemia Progression. Blood, 2019, 134, 5048-5048.	1.4	0

#	Article	IF	Citations
253	Novel SAHAâ€‘bendamustine hybrid NLâ€‘101 in combination with daunorubicin synergistically suppresses acute myeloid leukemia. Oncology Reports, 2020, 44, 273-282.	2.6	0
254	Expression of hypoxia-inducible factor-1a predicts benefit from rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in diffuse large B-cell lymphoma. International Journal of Clinical and Experimental Pathology, 2018, 11, 4472-4482.	0.5	0
255	Establishment and Characterization of a Human Primary Myelofibrosis Cell Line. Blood, 2021, 138, 4594-4594.	1.4	0
256	A Phase Ib Study of Linperlisib in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma. Blood, 2021, 138, 1386-1386.	1.4	0
257	Duration of Objective Responses for Patients with Indolent Non-Hodgkin Lymphoma Discontinuing Treatment before Progression: Analysis from the Phase III Chronos-3 Trial Comparing Copanlisib Plus Rituximab with Placebo Plus Rituximab. Blood, 2021, 138, 3538-3538.	1.4	0
258	A Risk Score Combined Clinical and Molecular Profiles Identifies a High-Risk Subgroup within AML1-ETO-Positive Acute Myeloid Leukemia. Blood, 2020, 136, 19-19.	1.4	0
259	Daratumumab, Bortezomib, Dexamethasone (D-Vd) Versus Bortezomib and Dexamethasone (Vd) in Relapsed or Refractory (RR) Multiple Myeloma (MM): Pooled Subgroup Analysis of Lepus and Castor. Blood, 2020, 136, 38-41.	1.4	0
260	Asia subpopulation analysis from the phase III POLARIX trial.. Journal of Clinical Oncology, 2022, 40, 7558-7558.	1.6	0